YourChoice Therapeutics CEO Akash Bakshi (left) and CSO Nadja Mannowetz
July 15, 2022 08:31 AM EDT
Financing
Startups

Ex­clu­sive: Af­ter Covid piv­ot, biotech nabs funds to be first in the clin­ic with a non-hor­mon­al con­tra­cep­tive for men

Kyle LaHucik

Senior Reporter

The goal was to cre­ate a non-hor­mon­al con­tra­cep­tive that women could take to pre­vent preg­nan­cy and po­ten­tial­ly STIs, but the Covid-19 pan­dem­ic caused Your­Choice Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Sage re­ports Phase 2 fail­ure in Hunt­ing­ton's dis­ease, ends drug's de­vel­op­ment

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

Pfiz­er taps on­col­o­gy head Boshoff as Dol­sten's chief sci­en­tif­ic of­fi­cer suc­ces­sor

Ex­clu­sive: For­mer Pfiz­er com­mer­cial chief An­gela Hwang to join Flag­ship

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times